Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in antisense oligonucleotide therapeutics

S T Crooke1, C F Bennett

  • 1Isis Pharmaceuticals, Inc., Carlsbad, California 92008, USA.

Annual Review of Pharmacology and Toxicology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.

Neurobiology of disease·2022
Same author

Pharmacology of antisense therapeutic agents : cancer and inflamination.

Methods in molecular medicine·2011
Same author

Case report; rabies in a heifer.

The British veterinary journal·2010
Same author

Antisense oligonucleotide therapeutics.

Expert opinion on investigational drugs·2005
Same author

Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.

Leukemia·2004
Same author

Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes.

Gene therapy·2003
Same journal

Navigating the Computational Landscape for Drug Repurposing.

Annual review of pharmacology and toxicology·2026
Same journal

Microplastics and Atherosclerosis: Mechanisms.

Annual review of pharmacology and toxicology·2026
Same journal

Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology.

Annual review of pharmacology and toxicology·2026
Same journal

<i>Caenorhabditis elegans</i> as a Model System for Environmental Mitotoxicants.

Annual review of pharmacology and toxicology·2025
Same journal

Introduction to the Theme "New Approaches, Technology, and Techniques That Advance Pharmacology and Toxicology".

Annual review of pharmacology and toxicology·2025
Same journal

A Mechanistic Framework for Repurposing FDA-Approved Drugs to Combat Antimicrobial Resistance: The Case of <i>Staphylococcus aureus</i>.

Annual review of pharmacology and toxicology·2025
See all related articles

Antisense oligonucleotides show promise as gene expression inhibitors. Research confirms their therapeutic potential, with ongoing work to enhance their properties and minimize side effects for drug development.

Area of Science:

  • Pharmacology and Molecular Biology
  • Oligonucleotide Therapeutics

Background:

  • Antisense oligonucleotides (ASOs) have advanced significantly as pharmacological agents.
  • Demonstrated selective gene expression inhibition via antisense mechanisms in vitro and in vivo.

Purpose of the Study:

  • To review the progress and challenges in antisense oligonucleotide development.
  • To highlight the importance of proper experimental design and controls for validating antisense activity.
  • To discuss pharmacokinetic properties, toxicology, and medicinal chemistry improvements.

Main Methods:

  • Literature review and synthesis of experimental findings.
  • Characterization of pharmacokinetic and toxicological profiles of first-generation ASOs.
  • Evaluation of medicinal chemistry modifications for improved oligonucleotide properties.

Related Experiment Videos

Main Results:

  • Selective gene inhibition by ASOs confirmed through rigorous experimentation.
  • Identification of non-antisense mechanisms of action for some oligonucleotides.
  • Characterization of phosphorothioate oligodeoxynucleotide pharmacokinetics and toxicology in various species.
  • Demonstration that chemical modifications enhance potency and alter pharmacokinetic profiles.

Conclusions:

  • Antisense oligonucleotides are potent tools for gene expression modulation.
  • Distinguishing antisense from non-antisense effects requires careful experimental design.
  • Medicinal chemistry offers avenues to optimize ASO therapeutic potential by improving efficacy and safety.